文献速递神经肌肉病

德国腓骨肌萎缩症的经济负担研究

Cost of illness in Charcot-Marie-Tooth neuropathy: Results from Germany.
PubMed 文献 · Neurology · 2019-03-27

该研究通过德国国家患者登记系统纳入397例基因确诊的腓骨肌萎缩症(CMT)患者,采用标准化问卷收集医疗利用、非正式照护及疾病相关支出等信息,从社会视角估算年度疾病成本。结果显示每例患者年总成本为22,362美元(95%CI 19,464–25,723),其中直接成本占67.3%,非正式照护成本为最高单项成本因素;多变量回归分析表明总成本随疾病严重程度增加,年龄、CMT亚型、合并症、体重指数和就业状态也是成本变化的预测因素(p<0.05)。

要点

  • CMT患者年人均总成本为22,362美元,直接成本占67.3%。
  • 非正式照护成本是最高单项成本因素。
  • 疾病严重程度、年龄、CMT亚型等可预测成本变化。

核心结论

  • CMT与显著的经济负担相关,首次评估的疾病成本可为卫生政策决策提供重要输入,尤其关乎疗法研发。
  • 患者报告的疾病严重程度感知与资源消耗相关。

研究设计与样本

  • 通过德国国家患者登记系统识别CMT患者,邀请完成标准化问卷,收集医疗利用、非正式照护及其他疾病相关支出和工作状况信息。
  • 基于社会视角估算年度疾病成本,纳入397例基因确诊的CMT患者。

主要发现

  • 每例患者年总成本为22,362美元(95%CI 19,464–25,723),直接成本占67.3%。
  • 最高单项成本因素为非正式照护成本。
  • 多变量回归显示总年成本随Charcot-Marie-Tooth神经病评分(疾病严重程度)增加,年龄、CMT亚型、合并症、体重指数和就业状态也是成本变化的预测因素(p<0.05)。
  • 总成本因婚姻状况、主观评估的损害、对他人的依赖、护理等级、教育水平和疾病病程而异。

临床怎么用

  • 临床中应关注CMT患者的非正式照护需求,其是成本的主要驱动因素。
  • 患者对疾病严重程度的主观感知与资源消耗相关,提示在评估与管理中需重视患者报告结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess cost associated with the disease-specific need of patients diagnosed with Charcot-Marie-Tooth neuropathies (CMT) in Germany. METHODS: Patients with CMT were identified through the national patient registry and invited to complete a standardized questionnaire. The data collected include information about health care use, informal care, and other disease-related expenses as well as the working situation. Based on this information, we estimated the annual cost of CMT from the perspective of society. RESULTS: This study included 397 patients with a genetically confirmed CMT diagnosis. We estimated total annual cost of illness (COI) of $22,362 (95% CI $19,464-$25,723) per patient, of which 67.3% were direct costs. The highest single cost factor was informal care cost. For Germany, we extrapolated total cost of CMT of $735.0 million ($639.8 million-$845.5 million). Multivariate regression analysis showed that total annual cost increased with disease severity (Charcot-Marie-Tooth Neuropathy Score). Age, CMT subtype, comorbidities, body mass index, and employment status were also predictors of a change in cost (p < 0.05). Moreover, we found differences in total cost depending on marital status, subjectively evaluated impairments, dependence on other persons, care level, educational level, and disease duration. CONCLUSIONS: CMT is associated with a substantial economic burden. For the first time, the COI of CMT has been assessed and will serve as important input to decision-making in health policy, especially regarding research and development of therapies. Moreover, our results indicate the importance of the patient-reported perception of disease severity related to the consumption of resources.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schorling E, Thiele S, Gumbert L, et al. Cost of illness in Charcot-Marie-Tooth neuropathy: Results from Germany. Neurology. 2019. PMID: 30918088. doi:10.1212/WNL.0000000000007376

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。